A new global partnership to improve surgical care: EORTC 1527 DREAM opens
28 Nov 2016
A landmark collaboration between Europe and Japan, the DREAM study (NCT02781935) (Diffusion-weighted magnetic resonance imaging to assess liver metastasis and improve surgical planning) has officially opened. This first intergroup study between EORTC’s Gastrointestinal Tract Cancer group, Japan Clinical Oncology Group (JCOG) – the leading cancer research network of Japan- and the European Society of Surgical Oncology (ESSO) will assess the accuracy of diffusion-weighted MRI in combination with other diagnostic modalities to predict complete response among patients with borderline resectable/unresectable colorectal liver metastasis who received conversion systemic therapy.
Surgical resection of liver metastasis still offers the best chance for cure for patients with colorectal liver metastasis. Improved imaging modalities and combinations of chemotherapy and targeted therapy have made it possible for patients with complex and extensive liver metastasis to undergo resection. In this process, some metastatic lesions might completely “disappear” in imaging. Whether this corresponds to true pathologic complete response or a durable clinical response is still debated. Thus, the management of “disappearing metastasis” by either resecting or leaving them behind remains a question. DREAM is the first international, multi-center and prospective study to assess the true nature of disappearing metastasis. It is also the first intergroup study between EORTC, ESSO and JCOG, three leaders in the field of cancer treatment and research. This is the first step in developing a tailored treatment for patients, with the objective to potentially decrease the risk of surgical complications.
DREAM will involve 16 European sites, 12 Japanese sites and 2 sites from the United States. An integrated quality assurance program involving surgery, imaging and pathology will be implemented in the study through the SURCARE platform led by EORTC. “DREAM marks the beginning of a dynamic collaboration between EORTC, ESSO and JCOG to develop prospective and innovative surgical clinical research, advocate quality assurance and pave the way for a unique educational exchange of a new generation of young researchers committed to cancer research across Europe and Japan,” said Serge Evrard, SURCARE Principal Investigator and EORTC Board member.
For more information about the collaboration between EORTC and JCOG, please go to https://www.ncbi.nlm.nih.gov/pubmed/27765814
For more information about SURCARE, please go to https://www.ncbi.nlm.nih.gov/pubmed/27828818
Related News
Meet the new EORTC Board
9 Jul 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
17 Jun 2024
Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group
24 May 2024
Clinical Trials Day 2024: a Q&A on pragmatic clinical trials
20 May 2024
EORTC/EMA workshop suggests an international way forward for treatment optimisation studies
8 May 2024
EORTC’s Participation at the ESTRO Congress 2024
29 Apr 2024
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024